Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review

Liping Qin; Yajun Li; Yizi He; Ruolan Zeng; Tao Pan; Yilang Zuo; Ling Xiao; Hui Zhou

doi:10.2147/OTT.S343400

Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review

Onco Targets Ther. 2022 Jan 6:15:1-11. doi: 10.2147/OTT.S343400. eCollection 2022.

Authors

Liping Qin^#^{1

2}, Yajun Li^#², Yizi He², Ruolan Zeng², Tao Pan², Yilang Zuo², Ling Xiao³, Hui Zhou²

Affiliations

¹ Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People's Republic of China.
² Department of Lymphoma and Hematology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China.
³ Department of Histology and Embryology of School of Basic Medical Science, Central South University, Changsha, Hunan, 410013, People's Republic of China.

^# Contributed equally.

Abstract

Primary central nervous system extranodal natural killer/T-cell lymphoma (PCNS ENK/TCL) is an extremely rare lymphoma. Only 23 cases of PCNS ENK/TCL have been reported in the English literature. Due to the rarity of this lymphoma, an effective therapeutic strategy has not been defined. Generally, this type of lymphoma is treated with surgery, intrathecal chemotherapy, and postoperative chemoradiation therapy. The prognosis is poor. Herein, we present a case of primary brain NK/T cell lymphoma in a 50-year-old immunocompetent Chinese female and review the literature. The patient underwent intracranial tumor resection and was subsequently treated with a PD1 monoclonal antibody (Sintilimab) combined with chemotherapy. The patient survived 15 months after diagnosis. This is the first report of PCNS ENK/TCL treated with surgery and chemotherapy combined with immunotherapy and suggests an effective treatment regimen for PCNS ENK/TCL.

Keywords: PD1; chemotherapy; extranodal natural killer/T-cell lymphoma; immunotherapy; primary central nervous system.

Publication types

Case Reports

Grants and funding

This work was supported by Changsha Municipal Natural Science Foundation (No. kq2014206); the Natural Science Foundation of Hunan Province National Health Commission (No. 20201659); the grants from the Hunan Provincial Science and Technology Department (No. 2017SK2130); the National Cancer Center (grant number NCC2017A20); the “Scientific Research Climbing Plan” of Hunan Cancer Hospital (grant number ZX2020003). the Hunan Provincial Natural Science Foundation of China (No. 2021JJ30425); the Natural Science Foundation of Hunan Province National Health Commission (No. 202203045455).